MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial.

@article{Luisetti1996MR889AN,
  title={MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial.},
  author={Maurizio Luisetti and Carlo Sturani and David M. Sella and Enzo R Madonini and V Galavotti and Guelfucci Bruno and Vittoria Peona and Umberto Kucich and Gustavo Dagnino and Joel Rosenbloom and Barry Starcher and Carlo Grassi},
  journal={The European respiratory journal},
  year={1996},
  volume={9 7},
  pages={1482-6}
}
We investigated whether MR889, a synthetic cyclic thiolic elastase inhibitor, administered for a period of 4 weeks to chronic obstructive pulmonary disease (COPD) patients, is well-tolerated, and whether it modifies biochemical indices of lung destruction. The study was a double-blind, randomized, placebo-controlled clinical trial in COPD patients. Thirty subjects were administered MR889 orally at a dose of 500 mg b.i.d. for 4 weeks, and 30 received placebo following the same schedule. In… CONTINUE READING